Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2023-04-06 00:00:00 ET · period of report 2023-04-04 · accession 0001162194-23-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-06 | 2023-04-04 | LAB | Egholm Michael | Pres, CEO, Dir | M - OptEx | $0.00 | +196.5K | 206.5K | +1,965% | $0 |
| D | 2023-04-06 | 2023-04-04 | LAB | Egholm Michael | Pres, CEO, Dir | M - OptEx | $0.00 | -196.5K | 589.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-04 | M | A | 196,512 | $0.00 | 206,512 | D | — | — | (F1) Includes 5,000 shares of Common Stock purchased pursuant to Fluidigm Corporation (currently Standard BioTools Inc.) 2017 Employee Stock Purchase Plan ("ESPP") for the purchase period of June 1, 2022 to November 30, 2022. |
| 2 | Derivative | Restricted Stock Units | 2023-04-04 | M | D | 196,512 | $0.00 | 589,537 | D | — · — to — | 196,512 Common Stock | (F2) Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. (F3) Restricted Stock Units vest in four equal annual installments beginning April 4, 2023. |